Experts review the current indications for NOACs as well as research on use as venous thromboembolism (VTE) prophylaxis in patients with cancer, who are critically ill, and with peripheral artery disease
Study authors assessed the effectiveness and safety of DOACs compared with warfarin in patients with valvular atrial fibrillation.
A 61-year-old woman presents to a rural emergency department with complaints of progressively worsening dyspnea for 24 hours and pleuritic chest pain.
The American Society of Hematology released evidence-based guidelines for the treatment of DVT and PE in patients without cancer.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Several questions remain regarding the effect of COVID-19 infection and hypercoagulation in the management of patients taking oral contraceptives, estrogen therapy, and patients who are pregnant.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Venous thromboembolism risk similar for patients with gout regardless of urate-lowering therapy.
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
